- Home
- CELC vs KAI Comparison
CELC vs KAI Comparison
Compare CELC & KAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CELC
- KAI
- Stock Information
- Founded
- CELC 2011
- KAI 1991
- Country
- CELC United States
- KAI United States
- Employees
- CELC N/A
- KAI N/A
- Industry
- CELC Medical Specialities
- KAI Industrial Machinery/Components
- Sector
- CELC Health Care
- KAI Industrials
- Exchange
- CELC Nasdaq
- KAI Nasdaq
- Market Cap
- CELC 3.1B
- KAI 3.6B
- IPO Year
- CELC 2017
- KAI N/A
- Fundamental
- Price
- CELC $100.23
- KAI $281.40
- Analyst Decision
- CELC Strong Buy
- KAI Buy
- Analyst Count
- CELC 7
- KAI 2
- Target Price
- CELC $95.29
- KAI $340.00
- AVG Volume (30 Days)
- CELC 916.2K
- KAI 141.6K
- Earning Date
- CELC 11-12-2025
- KAI 10-28-2025
- Dividend Yield
- CELC N/A
- KAI 0.49%
- EPS Growth
- CELC N/A
- KAI N/A
- EPS
- CELC N/A
- KAI 8.65
- Revenue
- CELC N/A
- KAI $1,024,074,000.00
- Revenue This Year
- CELC N/A
- KAI N/A
- Revenue Next Year
- CELC N/A
- KAI $8.96
- P/E Ratio
- CELC N/A
- KAI $32.11
- Revenue Growth
- CELC N/A
- KAI N/A
- 52 Week Low
- CELC $7.58
- KAI $244.87
- 52 Week High
- CELC $103.06
- KAI $423.86
- Technical
- Relative Strength Index (RSI)
- CELC 78.25
- KAI 55.74
- Support Level
- CELC $92.10
- KAI $244.87
- Resistance Level
- CELC $103.06
- KAI $284.54
- Average True Range (ATR)
- CELC 5.52
- KAI 9.28
- MACD
- CELC 0.74
- KAI 3.61
- Stochastic Oscillator
- CELC 90.84
- KAI 91.76
About CELC Celcuity Inc.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.
About KAI Kadant Inc
Kadant Inc. supplies process and engineering equipment for papermaking, recycling, lumber manufacturing, and related industries. The company's three reportable segments are the Flow Control segment which consists of the fluid-handling and doctoring, cleaning, & filtration product lines; the Industrial Processing segment which consists of the wood processing and stock-preparation product lines; and Material handling systems, which provides conveyor-belt equipment for industries such as mining, food processing, and packaging. The company has a geographic presence in the U.S., China, Asia, Germany, Canada, and Others.